Common and divergent neuroimaging features in major depression, posttraumatic stress disorder, and their comorbidity Authors: Jing Jiang, Stefania Ferraro, Youjin Zhao, Baolin Wu, Jinping Lin, Taolin Chen, Jin Gao, Lei Li Published: 2024 ABSTRACT AbstractPosttraumatic stress disorder (PTSD) and major depressive disorder (MDD) are common stress-related psychiatric disorders. Genetic and neurobiology research has supported the viewpoint that PTSD and MDD may possess common and disorder-specific underlying mechanisms. In this systematic review, we summarize evidence for the similarities and differences in brain functional and structural features of MDD, PTSD, and their comorbidity, as well as the effects of extensively used therapies in patients with comorbid PTSD and MDD (PTSD + MDD). These functional magnetic resonance imaging (MRI) studies highlight the (i) shared hypoactivation in the prefrontal cortex during cognitive and emotional processing in MDD and PTSD; (ii) higher activation in fear processing regions including amygdala, hippocampus, and insula in PTSD compared to MDD; and (iii) distinct functional deficits in brain regions involved in fear and reward processing in patients with PTSD + MDD relative to those with PTSD alone. These structural MRI studies suggested that PTSD and MDD share features of reduced volume in focal frontal areas. The treatment effects in patients with PTSD + MDD may correlate with the normalization trend of structural alterations. Neuroimaging predictors of repetitive transcranial magnetic stimulation response in patients with PTSD + MDD may differ from the mono-diagnostic groups. In summary, neuroimaging studies to date have provided limited information about the shared and disorder-specific features in MDD and PTSD. Further research is essential to pave the way for developing improved diagnostic markers and eventually targeted treatment approaches for the shared and distinct brain alterations presented in patients with MDD and PTSD. Introduction Posttraumatic stress disorder (PTSD) and major depressive disorder (MDD) are common stress-related psychiatric disorders associated with significant psychosocial and neurocognitive dysfunction (Godard et al., 2012; Thomas et al., 2010). Further, comorbid MDD is common in patients with PTSD, with approximately half of people with PTSD being diagnosed with comorbid MDD (Flory and Yehuda, 2015; Rytwinski et al., 2013). Prolonged trauma seems to be a major risk factor for comorbid PTSD and MDD (PTSD + MDD) (Kostaras et al., 2017). One explanation for the high comorbidity rate is that it may reflect overlapping symptoms of the two disorders, such as sleep disturbance, anhedonia, and concentration impairments (Flory and Yehuda, 2015). An alternative view is that the co-occurrence of PTSD and MDD possibly represents a subtype of PTSD (Flory and Yehuda, 2015). Individuals with PTSD + MDD tend to have more severe clinical symptoms and neurocognitive impairments (e.g. verbal memory and attention deficits), greater risk for suicidal behavior than individuals with PTSD or MDD alone (Dold et al., 2017; Nijdam et al., 2013; O'Donnell et al., 2004), and diminished overall treatment efficacy and increasing chronicity (Kaplan and Klinetob, 2000; Pukay-Martin et al., 2012). Recently, a meta-analysis of randomized controlled trials proved that the co-occurrence of depression may act as a risk factor for attenuated response in PTSD psychotherapies (Kline et al., 2021). Together, these issues call for intensive research on the overlaps and differences in the neural mechanisms in MDD and PTSD. A series of studies of various research areas have been conducted to deepen our understanding of the underlying mechanisms of MDD and PTSD, mainly involving genetic and epigenetic factors, gene–environment interactions, neurotransmitter systems, and neuroendocrine function. Genetic and epigenetic research has supported the viewpoint that PTSD and MDD may possess common and disorder-specific gene expression patterns, mainly associated with neuroendocrine and neurotransmitter systems. Specifically, previous genetics studies revealed that PTSD and MDD had consistent and opposing directionality of molecular findings in epigenetic processes and genes expression of glucocorticoid receptor and FK506 binding protein 51 (FKBP5) (Yehuda et al., 2015; Zannas and Binder, 2014). A recent cross-trait meta-analysis identified 29 genomic loci shared in PTSD and MDD, and held the view that MDD is influenced by a broader spectrum of causal gene variants than PTSD (Zhang et al., 2022). Moreover, one post mortem study performing RNA sequencing in the prefrontal cortex (PFC) and amygdala regions revealed that overlapping gene expression patterns were associated with decreased immune signaling and neuroinflammation in MDD and PTSD, and a limited number of PTSD-specific differentially expressed genes were associated with subpopulations of GABAergic inhibitory neurons (Jaffe et al., 2022). A positron emission tomography study reported lower monoamine oxidase-B levels in corticolimbic brain areas in PTSD with comorbid MDD compared with PTSD alone (Gill et al., 2022). In the aspect of gene-environment interaction, the most extensive analyses have focused on FKBP5 and have elucidated that interaction between FKBP5 genotype and childhood trauma is associated with increased risk for stress-related disorders including PTSD and MDD (Smoller, 2016). In terms of neuroendocrine function and neurotransmitter systems, common and distinct changes have been reported in MDD and PTSD. Concretely, the abnormal functioning of the hypothalamic–pituitary–adrenal axis has been supposed to play a key role in the development of PTSD and MDD (Dunlop and Wong, 2019; Pariante and Miller, 2001). Both MDD and PTSD were associated with alterations in dopaminergic (Ney et al., 2021; Shen et al., 2012) and serotonergic transmission (Dell'Osso et al., 2016; Southwick et al., 1999). Collectively, these genetic and neurobiology studies have contributed to setting a stronger foundation for research on the shared and distinct neuroimaging markers of MDD and PTSD. The mono-diagnostic and transdiagnostic neuroimaging studies have enabled qualitative and quantitative comparisons of MDD and PTSD, respectively. To date, numerous mono-diagnostic neuroimaging studies using magnetic resonance imaging (MRI) have identified functional and structural abnormalities in MDD and PTSD. Functional MRI (fMRI) studies have demonstrated alterations in core functional networks including the default mode network (DMN), executive control network (ECN), and salience network (SN) in both disorders (Albert et al., 2019; Bao et al., 2021). Similar effects of behavioral treatments on normalizing neural functional alterations have been reported (Shou et al., 2017; Yang et al., 2018a, 2018b). Common neural correlates in structural MRI have also been frequently found in the two disorders, including reduced gray matter volume in the insular and anterior cingulate cortices (ACC) (Bora et al., 2012; Bromis et al., 2018; O'Doherty et al., 2015). In summary, these mono-diagnostic neuroimaging studies provided indirect evidence for similar functional and structural abnormalities in MDD and PTSD. In the past two decades, a limited number of case-control transdiagnostic neuroimaging studies have focused on direct comparisons of MDD and PTSD, aiming to identify common and divergent underlying neural signatures. In particular, increasing attention has been paid to individuals with PTSD + MDD. Some studies examined the effects of MDD comorbidity on brain activity and structure in the context of PTSD (Kemp et al., 2007; Lanius et al., 2007; van Rooij et al., 2015). Advances in estimating the relevance/interaction effect between MDD and PTSD are now available. We therefore performed a systematic review to provide a more comprehensive knowledge of extant studies probing the similarities and differences in the underlying neural pathophysiology of MDD and PTSD in adult population, displaying the existing research gaps and making corresponding suggestions for future research. Of note, the summative conclusions may provide potential targets for neuroregulatory intervention in MDD and PTSD, especially comorbid MDD and PTSD. Methods The present review was conducted according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. We searched PubMed using the following key words: ‘MDD’ OR ‘major depressive disorder’ OR ‘depression’; ‘PTSD’ OR ‘posttraumatic stress disorder’ OR ‘post-traumatic stress disorder’; and ‘functional MRI’ OR ‘task-based’ OR ‘fMRI’ OR ‘resting-state’ OR ‘functional connectivity’ OR ‘diffusion’ OR ‘DTI’ OR ‘GMV’ OR ‘grey matter’ OR ‘gray matter’ OR ‘VBM’ OR ‘voxel-based morphometry’ OR ‘surface-based morphometry’ OR ‘cortical thickness’. The reference lists of the articles included in related review and meta-analyses were also checked for relevant studies. We screened 735 studies published before 30 August 2024, and included original neuroimaging studies that: (i) directly compared patients with PTSD and those with MDD; (ii) compared individuals with PTSD + MDD to those with PTSD alone or MDD alone; (iii) explored the effects of treatments on ameliorating depression and PTSD symptoms in patients with PTSD + MDD; and (iv) found potential neuroimaging features for classification of MDD and PTSD (MDD alone vs PTSD alone, MDD alone vs PTSD + MDD, or PTSD + MDD vs PTSD alone). Studies in children, adolescents or geriatrics were not included in the present review. We excluded studies that did not examine the neuroimaging features using MRI. We also excluded case reports and review articles, unless they included a meta-analysis. To provide supplementary information, we gave an overview of these meta-analyses providing a quantitative analysis of neuroimaging findings between PTSD and MDD. We extracted authors, year of publication, sample categories and size, neuroimaging methods, and key findings. Each enrolled cross-sectional study was assessed for quality by two independent reviewers (L.L. and J.J.) using a 12-point checklist adapted from previous meta-analytic studies (Brambilla et al., 2003; Shepherd et al., 2012). This checklist was modified to reflect critical variables essential in assessing the quality of included original studies. Each item was scored 1, 0.5, or 0 if the criteria were fully, partially or not met, respectively (summarized in Table S1). Additionally, we recorded the therapy, symptom relief, neuroimaging predictors, and treatment-related findings for studies in patients with PTSD + MDD. Results The literature search using PubMed yielded 735 results. We screened the titles and abstracts of these 735 records. Two original studies were not included as they enrolled patients with MDD or PTSD who experience own-thought auditory verbal hallucinations (Zhuo et al., 2020a, 2020b). It left 28 relevant studies for review (see Fig. 1). Among them, 17 original studies focused on the disease-related neural traits, including eight papers using resting-state fMRI (Averill et al., 2024; Gong et al., 2017, 2019a; Kennis et al., 2013; Koopowitz et al., 2023; Yuan et al., 2019; Zhu et al., 2017; Zilcha-Mano et al., 2020), six studies using task-based fMRI (Bryant et al., 2021; Keller et al., 2022; Kemp et al., 2007; Lanius et al., 2007; van Rooij et al., 2015; Whalley et al., 2009), and three structural MRI studies (Dai et al., 2020; Gong et al., 2019b; Kroes et al., 2011) (summarized in Table 1). The quality scores ranged from 10.5 to 11.5 (mean score 11.1) shown in Table S2, demonstrating that most included original studies were of relatively high quality. Five original studies explored the potential neural mechanisms and/or predictors of response to treatments in PTSD + MDD populations (Barredo et al., 2021; Dai et al., 2020; Henigsberg et al., 2011; Philip et al., 2018; Yang et al., 2018b) (summarized in Table 2). A total of seven meta-analyses have reported the shared and/or distinct neuroimaging findings between MDD and PTSD (Bromis et al., 2018; Janiri et al., 2020; Jenkins et al., 2016; McTeague et al., 2017; Schulze et al., 2019; Serra-Blasco et al., 2021; Wang et al., 2024) (summarized in Table 3). A graphical representation of the key brain regions with similar or distinct neuroimaging features among MDD alone, PTSD alone, and PTSD + MDD cohorts is shown in Fig. 2. Flow chart showing the selection of studies. Key brain regions that showed similar or distinct neuroimaging features among MDD alone, PTSD alone, and PTSD + MDD cohorts. Abbreviations: HIP, hippocampus; OFC, orbitofrontal cortex. Table 1:Findings of neuroimaging studies enrolling PTSD, MDD, and/or PTSD + MDD patients.PatientsHCNeuroimaging findingsStudyDiagnosis, participants, n (females, n), age, yearsparticipants, n (females, n), age, yearsAnalysis methodsComparisons (PTSD vs MDD; PTSD + MDD vs HC; PTSD + MDD vs MDD/PTSD; HC vs MDD/PTSD) and potential mechanisms (MDD or PTSD symptoms related) Resting-state fMRI Averill et al. (2024)PTSD/PTSD + MDD, 27 (0), 37.41; MDD, 22 (0), 33.87–longitudinal alterations of FC following a mild experimental stressor (DMN)PTSD-specific alterations: a stress-induced significant reduction in DMN strength; MDD-specific alterations: a stress-induced significant increase in DMN strength; main effect of group: significant reduction in DMN strength in the PTSD group compared to the MDD groupGong et al. (2019a)PTSD, 50 (34), 43.10; MDD, 50 (34), 38.89122 (64), 29.61effective connectivity (between the MDN and the cortex)HC vs MDD and HC vs PTSD: transdiagnostic feature: left MDN displayed significant effective connectivity increases with five regions including the right postcentral gyrus, left SMG, right putamen, right SMG/angular gyrus and right medial SFG; the right MDN displayed significant effective connectivity increases with five regions including the bilateral SMG, right postcentral gyrus, right medial SFG and left MCCGong et al. (2017)PTSD, 50 (34), 43.10; MDD, 50 (34), 38.89122 (64), 29.61FC analysis (DMN, CEN, SN)HC vs MDD and HC vs PTSD: transdiagnostic feature: both MDD and PTSD groups reductions in intranetwork connectivity of the DMN; PTSD vs MDD: no significant difference in internetwork connectivity among the HC, PTSD, and MDD groupsKennis et al. (2013)PTSD + MDD, 27 (0), 37.41; PTSD, 22 (0), 33.87–FC analysis (ROI: sgACC and insula)sgACC as seed: PTSD ± MDD ≤ PTSD, bilateral thalamus; PTSD ± MDD ≥ PTSD, perigenual ACC; bilateral insula as seeds: PTSD ± MDD ≤ PTSD, left HIP. PTSD ± MDD group: CAPS cluster B scores correlated negatively with connectivity of the sgACC with the perigenual ACC; PTSD group: CAPS cluster C scores correlated negatively with connectivity of the sgACC with the left thalamusKoopowitz et al. (2023)PTSD, 22 (22), 31.1; MDD, 18 (18), 28.2; PTSD + MDD, 17 (17), 30.428 (28), 26.1FC analysis (within and between SN, DAN, frontoparietal network, and DMNWithin DMN: PTSD ± MDD ≤ HC, ACC-left precuneus, precuneus-left hippocampal gyrus; PTSD ± MDD ≤ PTSD, ACC-left precuneus; MDD ≥ HC, ACC-left hippocampal gyrus, right angular gyrus-left hippocampal gyrus, right angular gyrus-right hippocampal gyrus, left precuneus-left hippocampal gyrus, right PCG-right hippocampal gyrus, right PCG-right precuneus; PTSD ≥ HC, ACC-left hippocampal gyrus; PTSD ≤ MDD, left precuneus-right precuneusWithin right frontoparietal network: PTSD ± MDD ≥ MDD, right dorsolateral PFC-right IPL, right IPL-right MTG, right IPL-left IPL, right IPL-left, right cingulate gyrus, right MTG- left IPL, left IPL-left, right cingulate gyrus; PTSD ± MDD ≥ PTSD, right dorsolateral PFC-right IPL; PTSD ± MDD ≥ HC, right dorsolateral PFC-right middle frontal, right MTG-left IPL; MDD ≤ HC and PTSD ≤ HC, right IPL-left IPLWithin left frontoparietal network: MDD ≤ HC, left middle frontal gyrus-left MTG, left middle frontal gyrus-left precuneus, left middle frontal gyrus-right IPL, left IFG-right IPL; MDD ≤ PTSD ± MDD, left middle frontal gyrus-left MTG, left middle frontal gyrus-right IPL, left IFG-left precuneus; MDD ≤ PTSD, left middle frontal gyrus-left MTG, left middle frontal gyrus-left precuneus, left IFG-left precuneus, left IFG-right IPL; PTSD ≤ HC, left middle frontal gyrus-right IPLBetween-network connectivity: no significant group effectYuan et al. (2019)PTSD + MDD, 18 (17), 45.3; PTSD, 28 (17), 45.850 (32) (TEHC), 45.0whole brain FC analysis (seeds: BLA, CMA)TEHC < PTSD (uncorrected): BLA-left ACC/SMA connectivity and BLA-right putamen/pallidum connectivity; PTSD + MDD < PTSD: right BLA connectivity with left ACC/SMA and bilateral putamen/pallidum; PTSD + MDD > PTSD: CMA connectivity with left ACC/SMA; TEHC vs PTSD + MDD: no significant difference; PTSD + MDD group: negative relationship between BLA-right putamen/pallidum connectivity and depression severity; PTSD alone group: no significant correlations between the FC values and depression severity; both patient groups: no correlation with FC values for PTSD symptomZhu et al. (2017)PTSD + MDD, 21 (14), 36.1; PTSD, 27 (15), 36.034 (23) (TEHC), 35.1between-ROI FC analysis (ROI: BLA, CMA, NAcc, orbitofrontal cortex, thalamus, HIP, and sgACC)TEHC vs PTSD: no significant difference; PTSD ± MDD ≤ PTSD: NAcc-thalamus, NAcc-HIP, BLA-orbitalfrontal cortex pathways; PTSD ± MDD ≤ TEHC: NAcc-thalamus, NAcc-HIP and BLA-orbitalfrontal cortex pathways; in all PTSD patients: AMYG pathway connectivity (BLA-orbitalfrontal cortex, CMA-thalamus) negatively correlated with PTSD symptom severity; MDD symptoms were negatively associated with the BLA-orbitalfrontal cortex and NAcc-thalamus pathwaysZilcha-Mano et al. (2020)PTSD + MDD, 52 (23), 43.9; PTSD, 51 (22), 40.676 (40) (TEHC), 40.8between-ROI FC analysis; machine learning: linear kernel support vector machine model; group analyses of the most discriminative featuresPTSD + MDD < PTSD: within connectivity in the BGN, and connectivity in BGN-other networks, SN–DMN, DAN–ECN, and SMN–other networks; PTSD + MDD > PTSD: within connectivity in the ECN, SN, and DAN; no significant correlation between depressive/PTSD symptoms and biomarkers identified from PTSD + MDD and PTSD alone classification Task-related fMRI Bryant et al. (2021)PTSD, 45 (24), 40.4; MDD, 26 (21), 31.525 (14) (TEHC), 45.1fMRI during an emotion processing task; hypothesized ROI (brain activation); whole-brain voxel-wise analysissubliminal processing of sad faces: (Sad vs Neutral, ROI): PTSD ≥ MDD, the left AMYG, caudate, putamen, right caudate and left pallidum; (Happy vs Neutral, ROI): no group differences; whole-brain voxel-wise analysis: no group differencesKemp et al. (2007)PTSD + MDD, 8 (5), 40.25; PTSD, 8 (NA), 35.3832 (20), 35.94fMRI during fear processing; hypothesized ROI (brain activation)PTSD alone ≥ HC: right AMYG; PTSD ± MDD ≤ PTSD alone: medial PFC and AMYG; PTSD ± MDD ≤ HC: left AMYGKeller et al. (2022)PTSD, 20(10), 43.4; MDD, 35 (17), 37.334 (17), 39.4fMRI during cognitive reappraisal; whole-brain fMRI analysis (brain activation), hypothesized ROI (brain activation), task-related FCwhole-brain fMRI analysis (reappraise > view): MDD ≤ HC, right triangular and opercular parts of the IFG, and right precentral gyrus; PTSD vs HC: no significant differences; MDD vs PTSD: no significant differences; negative correlations between clinical severity of anxiety or depression and activation of the right IFG during cognitive reappraisalhypothesized ROI (reappraise > view): HC ≥ MDD, left MTG, dorsomedial PFC, supplementary motor cortex as well as right dorsomedial PFC and IFG; HC ≥ PTSD, right dorsomedial PFC and IFG; MDD vs PTSD: no significant differencesFC (seed-to-voxel, right IFG as seed; reappraise > view): PTSD ≥ HC, left frontal orbital cortex, temporal pole, IFG, frontal operculum, and insula; HC ≥ MDD, none of the voxels survived correction; PTSD ≥ MDD, precuneus, anterior and PCG, bilateral paracingulate gyrus, bilateral SFG, left frontal orbital cortex, left temporal poleFC (voxel-to-voxel): PTSD ≥ HC, precuneus, PCG, bilateral lingual gyrus, bilateral intracalcarine cortex, bilateral cuneal cortex, right supracalcarine cortex and bilateral OC; MDD ≥ HC, precentral gyrus: PTSD ≥ MDD, right lateral OC, right angular gyrus, right MTG, right SMG, and right STGLanius et al. (2007)PTSD + MDD, 15 (11), 34.6; PTSD, 11 (7), 35.616 (13) (TEHC), 33.8fMRI during trauma script-driven imagery procedure; fMRI random effects analysis (brain activation)TEHC ≥ PTSD: bilateral dorsal ACC; right ventrolateral PFC; PTSD ≥ PTSD ± MDD: left insula; PTSD ± MDD ≥ PTSD: bilateral dorsal ACC; bilateral PCG; TEHC ≥ PTSD ± MDD: left thalamus; bilateral ventral ACC; bilateral ventromedial prefrontal cortices; right middle frontal gyrus; PTSD ± MDD ≥ TEHC: right dorsal ACC; bilateral PCGvan Rooij et al. (2015)PTSD + MDD, 16 (0), NA, PTSD, 13 (0), NA28 (0) (TEHC), 36.84; 25 (0) (HC), 35.38fMRI during trauma-unrelated emotional processing; hypothesized ROI (brain activation)PTSD ± MDD ≤ PTSD: sgACC response to neutral, negative and positive pictures; no significant correlation within the whole PTSD group was observed between PTSD severity and sgACC activityWhalley et al. (2009)PTSD, 16 (10), 36.8; MDD, 16 (12), 33.616 (10) (TEHC), 32.5fMRI during an episodic memory retrieval task; fMRI random effects analysis (brain activation)old > new contrast: PTSD ≥ TEHC, left dorsal AMYG and right middle OC; PTSD ≤ TEHC, right lateral PFC: PTSD ≥ MDD, left dorsal AMYG and right middle OC; PTSD ≤ MDD, right PFCemotional > neutral hit contrast: PTSD ≥ TEHC, left putamen and HIP, right precuneus, MCC and OC; PTSD ≥ MDD, left putamen and HIP, right precuneus, MCC and OCnegative > neutral hit contrast: PTSD ≥ TEHC, left SFG and right precuneus; PTSD ≤ TEHC, left STG; PTSD ≥ MDD, left SFG and right precuneus; PTSD ≤ MDD, left STGpositive > neutral hit contrast: PTSD ≥ TEHC, bilateral precentral gyrus, insula, right MTG, right MCC, right OC and right cerebellum; PTSD ≥ MDD, bilateral precentral gyrus, insula, right MTG, right MCC, right OC and right cerebellum structural MRI (T1WI) Dai et al. (2020)PTSD + MDD, 10 (5), 33.50; MDD, 11 (7), 37.8229 (15), 32.90tensor-based morphometry (brain volume)PTSD ± MDD ≤ HC: right opercular IFG; MDD ≤ HC: right opercular IFG and left orbital IFG; PTSD ± MDD vs MDD: no significant difference.MDD participants: significant correlation between opercular IFG volume and depressive severityGong et al. (2019b)PTSD, 91 (62), 42.73; MDD, 92 (49), 34.96201 (123), 29.61VBM (brain volume)HC vs MDD and HC vs PTSD: transdiagnostic feature: higher gray matter volume in bilateral putamenKroes et al. (2011)PTSD, 24 (15), 35.9; MDD, 29 (21), 33.429 (16) (TEHC), 32.45VBM (brain volume)PTSD vs MDD: no significant difference; combined clinical groups ≤ TEHC: MCC, medial PFC extending from the medial SFG at the precentral gyrus to the orbitofrontal cortex and ACC; right dorsolateral PFC spanning the middle frontal gyrus and SFG; PTSD group: negative relationship between brain volume in the right SFG, fusiform gyrus, lingual gyrus and left cuneus with depression severity; MDD group: positive relationship between brain volume in the bilateral cuneus and precuneus, and left fusiform gyrusAbbreviations: AMYG, amygdala; CAPS, Clinician Administered PTSD scale; CEN, central executive network; F, female; FC, functional connectivity; HIP, hippocampus; IFG, inferior frontal gyrus; IPL, inferior parietal lobule; MCC, midcingulate cortex; MDN, medio-dorsal thalamic nucleus; MTG, middle temporal gyrus; NR, not reported; OC, occipital cortex; PCG, posterior cingulate gyrus; SFG, superior frontal gyrus; SMA, supplementary motor area; SMG, supramarginal gyrus; SMN, sensorimotor network; STG, superior temporal gyrus; TEHC, trauma-exposed; T1WI, T1 weighted imaging. Findings of neuroimaging studies enrolling PTSD, MDD, and/or PTSD + MDD patients. Abbreviations: AMYG, amygdala; CAPS, Clinician Administered PTSD scale; CEN, central executive network; F, female; FC, functional connectivity; HIP, hippocampus; IFG, inferior frontal gyrus; IPL, inferior parietal lobule; MCC, midcingulate cortex; MDN, medio-dorsal thalamic nucleus; MTG, middle temporal gyrus; NR, not reported; OC, occipital cortex; PCG, posterior cingulate gyrus; SFG, superior frontal gyrus; SMA, supplementary motor area; SMG, supramarginal gyrus; SMN, sensorimotor network; STG, superior temporal gyrus; TEHC, trauma-exposed; T1WI, T1 weighted imaging. Table 2:Neuroimaging studies of treatment effects on the brain in PTSD + MDD patients. Patients, n (females, n), age, years HC, n (females, n), age, years Analysis methodsNeuroimaging findingsStudyTherapySymptom reliefPredictors (improved depressive symptoms and PTSD symptoms); Potential mechanisms (MDD/PTSD related)Barredo et al. (2019)PTSD + MDD, 21 (10), 52.0–Diffusion-weighted MRI; probabilistic tractography (frontal WM pathways: the forceps minor, ATR, cingulum, and uncinate fasciculi)TMS with targeted region in left DLPFC9 participantss met threshold response criterion for both PTSD and MDDPredictors for improved depressive symptoms: FA in bilateral ATR was marginally associated with left amygdala-to-left MPFC FC (uncorrected; right ATR (P); left ATR (N)); bilateral ATR FA accounted for significant variance in right amygdala-left MPFC FC predictor (uncorrected; right ATR (P); left ATR (N)); significant relationship between RD and right amygdala-left MPFC functional predictors (right ATR (N), corrected; left ATR (P), uncorrected)Predictors for improved PTSD symptoms: FA in bilateral ATR accounted for significant variance in left amygdala-to-left MPFC FC predictors (right ATR survived Bonferroni correction; right ATR (P); left ATR (N)); significant relationship between FA in bilateral ATR and right amygdala-to-left MPFC FC predictors (corrected; right ATR (P); left ATR (N)); significant effect of RD in ATR on right amygdala-to-left MPFC FC (uncorrected); FA in the forceps minor and bilateral ATR accounted for significant variance in right sgACC-left lateral PFC functional predictor (left right ATR and forceps minor (N), uncorrected; left ATR (P), corrected)Dai et al. (2020)PTSD + MDD, 10 (5), 33.529 (15), 32.90T1 weighted imaging; tensor-based morphometry (brain volume)ketamineboth depressive and PTSD symptoms were significantly improvedPotential Mechanisms, pre- vs posttreatment: no significant volume change; the volume of right opercular IFG showed a minor increase after treatment; pretreatment ≤ HC: right opercular IFG; posttreatment vs HC: no group differences in the volume of right opercular IFG; the correlations between local volume changes and depressive/PTSD symptoms were not assessedHenigsberg et al. (2011)PTSD + MDD, 11 (NA), NA–proton magnetic resonance spectroscopy (DLPFC)selective serotonin reuptake inhibitorsearly response to antidepressant treatment within 3–6 weeksPotential Mechanisms: significant increase in choline to creatine ratio from the first to the second spectroscopic scan during the antidepressant treatmentYang et al. (2018b)PTSD, 15 (15) (5 with comorbid MDD), 32.9; MDD, 16 (14), 34.619 (15), 33.4fMRI during emotional conflict task; whole-brain analysis (brain activation)12 weeks of either CBT for MDD or CPT for PTSDdepressive symptoms were significantly improved in both patient groupsPotential Mechanisms: increased activation of the left DLPFC was negatively correlated with depressive symptoms across all participants, and this brain-symptom association did not differ between MDD patients and those with PTSDPhilip et al. (2018)PTSD + MDD, 25(12), 51.8–resting-state fMRI; ROI-basic FC (sgACC, DLPFC, HIP, and BLA), data-driven MVPATMS with targeted region in left DLPFC12 and 11 participantss met threshold response criterion for PTSD and MDD, respectivelyPredictors for improved depressive symptoms: (pre-treatment) left BLA seed: increased FC with bilateral MPFC; right BLA seed: increased FC with frontopolar cortex; MVPA-derived clusters: right IPL, right dorsal ACC, left INS, and right superior temporal gyrusPredictors for improved PTSD symptoms: (pre-treatment) right sgACC seed: more negative FC with midline precuneus/PCC; more negative FC with left visual regions and medial/superior bilateral frontal regions of the DMN and SN; greater positive FC between sgACC and left IFG; left BLA seed: Increased FC with left MPFC; right BLA seed: increased FC with left VMPFC and frontopolar cortex; MVPA-derived clusters: right IPL, right amygdala, left parahippocampal gyrus, right DLPFC, and bilateral VMPFCPotential Mechanisms (MDD related): (post- vs pretreatment) sgACC seed: decreased FC of sgACC with midline precuneus/PCC, midline dorsal ACC and bilateral somatosensory/motor regions; anterior HIP seed: FC between the anterior HIP and multiple SN regions (right INS, left IPL), and left putamen; MVPA-derived clusters: right INS, midline dorsal ACC, left ACC, right caudate, bilateral motor cortex, and right fusiform gyrusPotential Mechanisms (PTSD related): (post- vs pretreatment) sgACC seed: decreases in FC between right sgACC and left precuneus/PCC, dorsal ACC, left DLPFC, bilateral INS, and visual regions; anterior HIP seed: decreases in anterior hippocampal FC with midline dorsal ACC, right INS, and left putamen; MVPA-derived clusters: bilateral motor cortex, left HIP, left VMPFC, left medial frontal gyrus, left dorsal ACC, right caudate, left putamen, left fusiform and right amygdalaAbbreviations: CBT, cognitive behavioral therapy; CPT, cognitive processing therapy; DLPFC, dorsolateral PFC; F, female; FC, functional connectivity; HIP, hippocampus; IFG, inferior frontal gyrus; INS, insula; IPL, inferior parietal lobule; MPFC, medial PFC; MVPA, multivoxel pattern activation; N, negative; NA, not available; P, positive; RD, radial diffusivity; VMPFC, ventromedial PFC; WM, white matter. Neuroimaging studies of treatment effects on the brain in PTSD + MDD patients. Abbreviations: CBT, cognitive behavioral therapy; CPT, cognitive processing therapy; DLPFC, dorsolateral PFC; F, female; FC, functional connectivity; HIP, hippocampus; IFG, inferior frontal gyrus; INS, insula; IPL, inferior parietal lobule; MPFC, medial PFC; MVPA, multivoxel pattern activation; N, negative; NA, not available; P, positive; RD, radial diffusivity; VMPFC, ventromedial PFC; WM, white matter. Table 3:Shared and/or distinct neuroimaging findings between MDD and PTSD cohorts revealed by these meta-analyses. Imaging methodsNumber of studies Meta-analysis toolsStudyMDDPTSDothersMain findings of MDD and PTSD Task-related fMRI McTeague et al., 2017whole brain, activation (cognitive control)246schizophrenia, 135; obsessive compulsive disorder, 25, etc.ALETransdiagnostic abnormalities: abnormal activation in the left PFC, as well as anterior insula, right ventrolateral PFC, right intraparietal sulcus, and midcingulate/pre-supplementary motor areaSchulze et al., 2019whole brain, activation (affective processing)3214borderline personality disorder, 24SDM v5.141Diagnosis-specific meta-analyses: MDD ≥ HC, the right posterior insula, right rolandic operculum, right postcentral gyrus, right inferior occipital gyrus, bilateral median cingulate/paracingulate gyri, left caudate nucleus, right anterior cingulate/paracingulate gyri, and a cluster comprising the thalamus; MDD ≤ HC, the right amygdala, right inferior temporal gyrus, left superior parietal gyrus, left precentral gyrus, right middle frontal gyrus, left insula, and left IFG, triangular. PTSD ≥ HC, the orbital and triangular parts of left IFG, bilateral striatum (encompassing parts of the right amygdala), and left MTG; PTSD ≤ HC, bilateral postcentral gyrus, right superior temporal gyrus, and right insula (voxel-level uncorrected P < 0.005, cluster-level threshold of k ≥ 20 voxels)Comparison of MDD and PTSD: PTSD ≥ MDD, the left IFG (including ventrolateral PFC), bilateral amygdala and hippocampus, bilateral striatum, left MTG, left dorsolateral SFG and the right middle frontal gyrus. MDD ≥ PTSD: no suprathreshold clustersTransdiagnostic abnormalities: hyper-activation of the right median cingulate gyrus as well as hypo-activations of the right middle frontal gyrus and the right middle occipital gyrusJaniri et al., 2020whole brain, activation8335bipolar disorder, 66; anxiety disorders, 42ALEPooled analysis: transdiagnostic hypoactivation were identified centered in the right inferior PFC/insula, inferior parietal lobule, and putamenDiagnosis-specific meta-analyses: did not identify any additional disorder-specific clusters of hypo- or hyperactivation in diagnosis-specific meta-analyses of MDD and PTSDWang et al., 2024whole brain, activation12535–SDMTransdiagnostic abnormalities: increased neural activation in the bilateral inferior frontal gyrusComparison of MDD and PTSD: PTSD ≥ MDD, the right insula, left supplementary motor area extending to median cingulate gyrus and SFG, and left fusiform gyrus; PTSD ≤ MDD: the right posterior cingulate gyrus, right MTG, right paracentral lobule, and right inferior parietal gyrus Structural MRI (gray matter) Bromis et al., 2018ROI, volumeNR66–Hedges' g (Cohen effect size with small-sample correction)Meta-analysis in PTSD: PTSD ≤ HC, brain volume, intracranial volume, and volumes of the insula (left, right, and total), SFG, left MTG, inferior temporal gyrus, anterior cingulate (left and total), rostral ACC, lateral orbitofrontal cortex, and total amygdalaComparison of MDD and PTSD: PTSD ≤ MDD, total brain volume; PTSD ≥ MDD, the thalamus volumeTransdiagnostic abnormalities: smaller hippocampal volume compared with HCSerra-Blasco et al., 2021whole brain, VBM4512anxiety disorders, 20SDM v.6.21Diagnosis-specific meta-analyses: MDD ≤ HC, the bilateral cerebellum and left IFG (P < 0.05, TFCE corrected), as well as the right IFG including bilateral insula, left SFG including anterior cingulate subregions and right ventromedial PFC, bilateral hippocampi and left rolandic operculum including right posterior cingulum (P < 0.01, uncorrected). MDD ≥ HC, no regional GMV increases. PTSD ≤ HC, the left lingual gyrus extending to fusiform gyrus and the bilateral SFG (P < 0.05, TFCE corrected), as well as the left postcentral gyrus, right fusiform gyrus, left calcarine fissure, left parahippocampal. and left middle cingulate cortex (P < 0.01, uncorrected); PTSD ≥ HC, no regional GMV increasesComparison of MDD and PTSD: no significant differences at any explored thresholdTransdiagnostic abnormalities: no significant results (P < 0.05, TFCE corrected); reduced GMV in the left middle cingulate cortex (P < 0.01, uncorrected) Structural MRI (white matter) Jenkins et al., 2016whole brain, FA124bipolar disorder, 10; social anxiety disorder, 3; obsessive-compulsive disorder, 8SDM v.4.31Pooled analysis: transdiagnostic reduced FA were identified in several clusters, including the left forceps minor of the corpus callosum/ATR/inferior fronto-occipital fasciculus/uncinate fasciculus, left SLF, left cerebellum, left superior corona radiata/corticospinal tract, and right SLFDisorder-specific meta-analyses: MDD ≤ HC, left ATR, bilateral SLF, right cerebellum, and left inferior fronto-occipital fasciculus/uncinate fasciculus; PTSD ≤ HC, left uncinate fasciculus, left SLF, left cingulum, and right inferior longitudinal fasciculusThese regions of reduced FA in PTSD did not overlap with those of other disordersAbbreviations: ALE, activation likelihood estimation; CT, cortical thickness; ES, effect size; GMV, gray matter volume; IFG, inferior frontal gyrus; MTG, middle temporal gyrus; NR, not reported; SDM, seed-based d mapping; SFG, superior frontal gyrus; SLF, superior longitudinal fasciculus; TFCE, threshold-free cluster enhancement. Shared and/or distinct neuroimaging findings between MDD and PTSD cohorts revealed by these meta-analyses. Abbreviations: ALE, activation likelihood estimation; CT, cortical thickness; ES, effect size; GMV, gray matter volume; IFG, inferior frontal gyrus; MTG, middle temporal gyrus; NR, not reported; SDM, seed-based d mapping; SFG, superior frontal gyrus; SLF, superior longitudinal fasciculus; TFCE, threshold-free cluster enhancement. Functional MRI in PTSD and MDD Comparisons between PTSD and MDD We identified three task-based fMRI studies directly comparing the MDD and PTSD groups (Bryant et al., 2021; Keller et al., 2022; Whalley et al., 2009). The region of interest (ROI) fMRI study by Bryant et al. reported that patients with PTSD demonstrated significantly greater activation than MDD in multiple regions involved in amygdala and striatal-subcortical pathways during an emotion processing task (Bryant et al., 2021). Common effects across MDD and PTSD groups relative to controls were not explored in that study. Furthermore, Whalley et al. demonstrated greater activation during the memory retrieval process in patients with PTSD compared to depressed group in multiple brain regions including amygdala, hippocampus, and insula, while areas of shared alteration relative to healthy controls (HC) were not reported (Whalley et al., 2009). In addition, Keller et al. reported less focal neural activation in the right dorsomedial PFC and inferior frontal gyrus during cognitive reappraisal in both MDD and PTSD relative to HC, as well as MDD-specific reduced activation in the left middle temporal cortex and supplementary motor cortex (Keller et al., 2022). Notably, Keller et al. found clinical group differences in multiple regions involving DMN, SN, ECN, and auditory network using the seed-to-voxel and voxel-to-voxel functional connectivity (FC) analyses during cognitive reappraisal process, emphasizing the PTSD-specific features of overactive and hyperconnected SN (Keller et al., 2022). Despite involving various trauma events, these studies showed that MDD and PTSD had shared hypoactivation in the PFC, a region critical for threat detection and evaluation, and inhibitory control of emotion and memory expression, while higher activation in SN and fear processing regions including amygdala, hippocampus, and insula was mainly observed in PTSD relative to MDD group during cognitive and emotional processing (Fig. 2). One relevant study found that left dorsolateral PFC activation during a cognitive control task was negatively correlated with depression severity across MDD and PTSD (Yang et al., 2018b), suggesting the common neural alteration possibly associated with the overlapping depressive symptoms. These meta-analyses based on task-related fMRI studies have provided additional information to support the viewpoint that MDD and PTSD may have transdiagnostic and disorder-specific features in brain function during the execution of tasks, mainly involving the SN and fear processing regions (Janiri et al., 2020; McTeague et al., 2017; Schulze et al., 2019; Wang et al., 2024). Aiming to investigate transdiagnostic and disorder-specific neural abnormalities during the processing of negative affective stimuli, Schulze et al. conducted comparative meta-analyses in task-related fMRI studies in borderline personality disorder, MDD, and PTSD (Schulze et al., 2019). Results for individual disorders demonstrated decreased activation in the right amygdala in MDD contrasting with enhanced activation in PTSD compared with HC. Directly compared to MDD, individuals with PTSD showed enhanced activation in the left inferior and superior frontal gyri, right middle frontal gyrus, and bilateral amygdala and hippocampus. Conjunction analysis identifying the transdiagnostic neural activation illustrated a hyperactivation of the right median cingulate gyrus as well as hypoactivation of the right middle frontal gyrus and middle occipital gyrus. Another meta-analysis of task-related fMRI studies by Janiri et al. identified transdiagnostic clusters of hypoactivation in regions primarily involved in inhibitory control and salience processing (i.e. inferior PFC/insula, inferior parietal lobule, and putamen) across psychiatry disorders including MDD and PTSD (Janiri et al., 2020). Moreover, a transdiagnostic neuroimaging meta-analysis by McTeague et al. investigated the neural circuitry disruptions underlying cognitive control processing across psychiatric disorders including MDD and PTSD (McTeague et al., 2017). This study revealed abnormal activation in multiple regions, such as the PFC, anterior insula, and so on. Recently, the meta-analysis by Wang et al. also supported the viewpoint that PTSD and MDD share similar neural activation in the PFC (Wang et al., 2024). In addition, we identified four resting-state fMRI studies that compared MDD and PTSD directly (Averill et al., 2024; Gong et al., 2017, 2019a; Koopowitz et al., 2023). Among them, the two studies by Gong et al. enrolled patients with PTSD who had experienced the same trauma event of 2008 Sichuan earthquake (Gong et al., 2017, 2019a). Focusing on networks of interest (i.e. DMN, ECN, and SN), Gong et al. revealed transdiagnostic reductions in intra-network connectivity of the DMN and no significant difference in inter-network connectivity among HC, PTSD, and MDD groups (Gong et al., 2017). Another study by Gong et al. applied psychophysiological interaction analysis to measure the resting-state effective connectivity between the medio-dorsal thalamic nucleus and rest of the cortex (Gong et al., 2019a). In this study, Gong et al. identified transdiagnostic features of stronger effective connectivity between the medio-dorsal thalamic nucleus and neocortex (several prefrontal and parietal regions bilaterally such as postcentral gyrus, supramarginal gyrus, and medial superior frontal gurus) in medication-naïve MDD and PTSD cohorts relative to the HC. Koopowitz et al. recently recruited mothers at the 18-month postpartum time point and divided them into four groups: PTSD, MDD, PTSD + MDD, and controls (Koopowitz et al., 2023). FC within and between higher order cognitive control networks, including the SN, dorsal attention network (DAN), frontoparietal network, and DMN were compared across the four groups. Koopowitz et al. found that PTSD with comorbid MDD showed greater intrinsic FC within the right frontoparietal network, relative to the controls and the mono-diagnostic groups. Compared to PTSD group and controls, MDD group showed greater FC within the DMN, and weaker FC within the left frontoparietal network. No group differences in inter-network connectivity were observed in this study. Recently, Averill et al. compared the longitudinal alterations of DMN strength following a mild experimental stressor in MDD and PTSD (Averill et al., 2024). This study revealed a stress-induced reduction in DMN strength in PTSD group while increased DMN strength in MDD group. Notably, the researchers also demonstrated a significant main effect of group, showing significantly reduced DMN strength in the PTSD group relative to MDD group. Overall, these fMRI studies support the viewpoint that DMN dysfunctions, especially a functional impairment of the PFC, are implicated in the pathophysiology of MDD and PTSD. A fuller presentation of findings of these original fMRI studies is shown in Table 1. Comparisons between PTSD + MDD and PTSD alone Patients diagnosed with PTSD might have either subthreshold depression or meet criteria for MDD. Individuals with PTSD + MDD often exhibit greater functional and occupational impairments and poorer treatment response than participants with PTSD alone (Kessler et al., 2005), raising interest in underlying neurobiological differences and similarities between patients with PTSD alone and those with PTSD + MDD. In the present review, we identified three task-related neuroimaging studies examined the effects of MDD comorbidity on neural activity in the context of PTSD (Kemp et al., 2007; Lanius et al., 2007; van Rooij et al., 2015). During a trauma script-driven imagery procedure, Lanius et al. found that both PTSD + MDD and PTSD alone groups revealed decreased brain activation in the ACC and right ventrolateral PFC relative to traumatized controls, whereas the PTSD + MDD group had lower insula activation, less reduction in ACC and higher posterior cingulate cortex (PCC) activation versus patients with PTSD alone (Lanius et al., 2007). Another fMRI study reported that decreased subgenual ACC (sgACC) activation was related to the MDD status within the PTSD group during trauma-unrelated emotional processing (van Rooij et al., 2015). The opposite findings in the ACC of the two studies (Lanius et al., 2007; van Rooij et al., 2015) possibly relate to the various trauma type (veteran experience vs motor vehicle accident) and imagery procedure stimuli (trauma-driven vs trauma-unrelated), but this needs further examination. Some fear-related regions such as amygdala and PFC in PTSD are more likely to be activated by negative stimuli than they are in PTSD + MDD. Supporting this view, Kemp et al. found lower activity in the amygdala and medial PFC in response to fear stimuli in patients with PTSD + MDD compared to patients with PTSD alone (Kemp et al., 2007). Of special interest, the PTSD alone group in this study showed increased activation in the right amygdala while the PTSD + MDD group showed decreased activation in the left amygdala relative to the HC. As the most common fMRI finding in individuals with PTSD, amygdala hyperactivity has been thought to facilitate associative fear learning and result in stronger fear associations (Harnett et al., 2020). The findings of Kemp et al. hinted the effects of comorbid depression on amygdala activation in the context of PTSD. Several resting-state fMRI studies investigating whether PTSD + MDD comorbidity holds an underlying neural basis different from PTSD alone have focused on regions related to fear and reward processing, such as ACC, insula, amygdala, and nucleus accumbens (NAcc) (Fig. 2). The study by Kennis et al . used the sgACC and insula as seeds to investigate whether or not comorbid MDD contributes to the FC alterations in veterans with PTSD (Kennis et al., 2013). Kennis et al. found that FC of the sgACC with the thalamus and perigenual parts of the ACC can distinguish PTSD + MDD from PTSD alone, suggesting that these features may serve as a neurobiological marker for comorbid depression in PTSD population (Kennis et al., 2013). Besides, Kennis et al. also reported that reduced FC of insula-hippocampus in PTSD + MDD relative to PTSD alone might be due to medication effects, raising an issue that needs more attention in future research. The amygdala, another core region in the fear circuit, has been suggested to be involved in the pathophysiology of both PTSD and MDD. Recent studies have identified the specialized roles of basolateral (BLA) and centromedial amygdala (CMA) during fear conditioning (Ciocchi et al., 2010; Mahan and Ressler, 2012). Considering the dissociable functions of the BLA and CMA, Zhu et al. conducted the first study investigating amygdala FC at the subregional level between PTSD alone and PTSD + MDD with seeds of BLA, CMA, and NAcc (Zhu et al., 2017). They found that PTSD + MDD group exhibited weaker FC of BLA-orbitofrontal cortex, Nacc-thalamus, and NAcc-hippocampus relative to either PTSD alone or trauma-exposed HC, whereas there was no significant difference between PTSD alone and trauma-exposed HC, suggesting that deficits in NAcc and amygdala pathways involved in fear and reward processing are prominently and selectively altered in PTSD + MDD. The findings of Zhu et al. are consistent with evidence that individuals with PTSD + MDD have more severe illness and need more robust intervention. To eliminate the potential influences of predefined ROI, various trauma types and medication treatment, Yuan et al. performed a whole-brain group analysis to comprehensively explore the functional networks involving the subregional amygdala in drug-naïve individuals with PTSD + MDD and PTSD alone exposed to the same massive earthquake (Yuan et al., 2019). Yuan et al. found that weaker BLA-right putamen/pallidum connectivity in PTSD + MDD was related to comorbid depression severity, as opposed to greater PTSD symptom severity in PTSD + MDD. In addition, PTSD + MDD group also showed weaker FC between right BLA with left ACC/supplementary motor area and left putamen/pallidum, as well as greater CMA connectivity with left ACC/supplementary motor area. These findings suggest that specific FC dysfunctions may distinguish PTSD + MDD from PTSD alone at the whole-brain level. In line with this view, Zilcha-Mano et al. further demonstrated the clinical utility of within- and between-networks connectivity features in differentiating individuals with PTSD alone from those with PTSD + MDD by means of a support vector machine model with accuracy achieving 76.7% (Zilcha-Mano et al., 2020). The most discriminative features included within-network FC in the basal ganglia network (BGN), DAN, and SN. Group analysis of these FC biomarkers demonstrated higher within-network connectivity in the BGN but lower within-network connectivity in the ECN, SN, and DAN in PTSD alone, versus PTSD + MDD. Overall, these studies propose proof for the effects of comorbid MDD on the brain in PTSD populations, suggesting the potential application of neuroimaging markers in differential diagnosis of PTSD. Structural MRI in PTSD and MDD Although past mono-diagnostic neuroimaging studies demonstrated that PTSD and MDD may share similar abnormalities in neuroanatomical substrates, few studies have contrasted the neuroanatomical alterations in MDD with those in PTSD. In the present review, we identified two studies using voxel-based morphometry (VBM) (Gong et al., 2019b; Kroes et al., 2011), and one study using tensor-based morphological method (Dai et al., 2020). Various trauma types, analysis methods and sample types of these structural MRI studies make it impossible to make any summative conclusions. Specifically, Kroes et al. used VBM analysis to identify associated volumetric changes of PTSD and MDD, versus trauma-exposed HC. The research group found similar volume reductions predominantly in prefrontal areas (i.e. middle cingulate gyrus, medial PFC, ACC, orbitofrontal cortex, and dorsolateral PFC) but no significant difference between PTSD and MDD (Kroes et al., 2011). Considering the similar levels of depression severity in the PTSD and MDD groups, Kroes et al. suggested that existing findings of gray matter reductions in prefrontal areas may not be specific to PTSD but rather related to features shared with other conditions, such as depression. In another VBM study, Gong et al. identified a transdiagnostic marker of increased putamen volume in four psychiatric groups (i.e. PTSD, MDD, obsessive-compulsive disorder, and psychosis) relative to HC by diagnosis-specific comparisons (e.g. PTSD vs HC, and MDD vs HC) (Gong et al., 2019b). It is worth noting that the comorbid disorders of these participants were not recorded, and the research group did not conduct a direct comparison between MDD and PTSD in this study. Using tensor-based morphological analysis, Dai et al. investigated the regional volume differences for 29 HC participants and 21 patients with MDD, including 10 participants with comorbid PTSD (Dai et al., 2020). They found that both MDD alone and PTSD + MDD groups showed smaller volume in right opercular inferior frontal gyrus relative to HC, only the MDD alone group showed smaller volume in left orbital inferior frontal gyrus compared to HC, and no significant difference was found between the MDD alone and PTSD + MDD groups (Table 1). The reliability and reproducibility of the findings need to be further verified in view of the small sample size. To provide more information, we also paid attention to relevant studies aiming to identify specific depression-related neuroanatomical abnormalities in the context of PTSD. Using FreeSurfer to analyze the volume of hippocampal subfields, Averill et al. provided the first evidence relating both PTSD and depression symptoms to structural alteration in the hippocampus-amygdala transition area, one region highly connected to prefrontal-amygdala circuitry, while dentate gyrus abnormalities were associated with depression severity but not PTSD symptoms (Averill et al., 2017). Several meta-analyses of structural MRI studies have been conducted recently to provide additional information. Bromis et al. conducted a statistical comparison of the ROI meta-analysis of PTSD with a previous meta-analysis of MDD (Bromis et al., 2018). Both PTSD and MDD showed reduced hippocampal volume compared to HC, with no difference between the patient groups in this region. Compared to patients with PTSD and HC, patients with MDD had significantly reduced thalamus volume. Patients with PTSD had reduced total brain volume, relative to MDD and HC. Serra-Blasco et al. recently analyzed common and specific gray matter volume characteristics by conducting a meta-analysis of VBM studies of MDD, anxiety disorders, and PTSD with samples with no or minimal percentages of comorbidities (Serra-Blasco et al., 2021). The pairwise comparison results (MDD vs PTSD) showed no significant difference for MDD and PTSD, whereas the conjunction analysis did show that the two disorders shared gray matter reduction in the left middle cingulate cortex when applying a more liberal threshold (P < 0.01, uncorrected). From a connectomic perspective, the Enhancing Neuroimaging Genetics through Meta-Analysis (ENIGMA)–Psychiatric Genomics Consortium used cortical thickness to construct structural covariance networks, and then calculated the cortical thickness-based centrality, a measure that characterizes the number of connections of a region. The researchers found that participants with PTSD + MDD showed higher centrality in the medial PFC and lower centrality in right visual cortex compared to PTSD alone (Rakesh et al., 2023). Synthesizing the findings of these original studies and meta-analyses, we concluded that structural abnormalities in the PFC would be the most reliable findings across MDD and PTSD. To identify transdiagnostic white matter alterations, Jenkins et al. conducted transdiagnostic meta-analysis and disorder-specific meta-analyses of fractional anisotropy (FA) studies across five emotional disorders including MDD and PTSD (Jenkins et al., 2016). The transdiagnostic meta-analysis revealed commonalities in reduced FA in emotional disorders compared to HC in multiple white matter tracts, including the left anterior thalamic radiation (ATR), bilateral superior longitudinal fasciculi, and so on. The disorder-specific meta-analyses showed that the two largest peaks of reduced FA in MDD contrasts were in the left ATR and superior longitudinal fasciculus. Reduced FA in the left uncinate fasciculus and superior longitudinal fasciculus was identified in the PTSD contrasts, however, the two regions were inferior to those identified in MDD. To sum up, the PTSD group was the most distinct, with no clusters of reduced FA overlapping with any other emotional disorders. Yielding the largest studies, the ENIGMA Consortium examined the overlap in white matter deficit patterns across disorders (Kochunov et al., 2022). The researchers adopted diffusion tensor imaging analytic workflow based on tract-based spatial statistics to extract 24 regional tractwise FA values for the entire white matter skeleton. They demonstrated that white matter deficits of PTSD showed only weak parallels with those seen in MDD. The two meta-analyses of FA studies support the anatomical specificity of white matter deficits in MDD and PTSD (Jenkins et al., 2016; Kochunov et al., 2022). Although these gray and white matter structural findings derived from secondary analyses of these original studies need further verification, they raise awareness of the potential importance of further studying the common and unique neuroanatomical alterations associated with MDD and PTSD. Potential neural mechanisms and predictors of response to treatments in PTSD + MDD populations To date, a series of reviews have summarized the clinical application of these therapeutic methods in treating MDD and PTSD mainly including antidepressants (e.g. selective serotonin reuptake inhibitors, serotonin/norepinephrine reuptake inhibitors, and ketamine), repetitive transcranial magnetic stimulation (TMS), and psychological intervention (e.g. acceptance and commitment therapy, cognitive therapy, and cognitive behavioral therapy) (Akhtar and Pilkhwal Sah, 2021; Cui et al., 2024; Hidalgo and Davidson, 2000; Hung et al., 2011; Jeffreys et al., 2012). Given that individuals with PTSD + MDD tend to have more severe clinical symptoms and greater risk for suicidal behavior compared to patients with PTSD alone or MDD alone, we therefore specifically focused on these studies exploring the underlying neural mechanisms of therapeutic effects that may correlate with the overlapped and/or disorder-specific neuroimaging features in PTSD + MDD populations. So far, a limited number of MRI studies have purely investigated the potential neural mechanisms of therapeutic response in PTSD + MDD populations, mainly involving selective serotonin reuptake inhibitors, ketamine, and repetitive TMS. Antidepressant medication There is increasing evidence to support the use of antidepressants, particularly the selective serotonin reuptake inhibitors, as first-line therapy in MDD and PTSD (Akhtar and Pilkhwal Sah, 2021; Cui et al., 2024; Hidalgo and Davidson, 2000). Enrolling patients with PTSD + MDD, Henigsberg et al. measured changes of neuronal marker N-acetyl-aspartate, choline (CHO), and creatine using proton magnetic resonance spectroscopy in responders to antidepressant treatment with selective serotonin reuptake inhibitors (Henigsberg et al., 2011). They found significant increase in choline/creatine ratio following the antidepressant treatment, suggesting increased turnover of cell membranes as a mechanism of the antidepressant drug therapy. Of note, research into pharmacotherapy for PTSD + MDD indicated that higher doses of antidepressant drugs may be needed than for patients with PTSD alone (Chiba et al., 2016). Available first-line antidepressant medications require several weeks to produce a full therapeutic response, and many patients fail to achieve remission. Thus, regarding individuals with PTSD + MDD, most attention has been focused on the antidepressant ketamine, an N-methyl-D-aspartate (NMDA) glutamate receptor antagonist that can rapidly (within 1 day) produce an antidepressant response and treat suicidality (Feder et al., 2014; Kritzer et al., 2022; Zarate et al., 2006). Neuronal atrophy and glutamatergic signaling dysfunction catalyzed by stress have been implicated in cognitive deficits associated with PTSD and depression (Millan et al., 2012; Musazzi et al., 2013; Popoli et al., 2011). Ketamine has shown potential as a novel glutamate-targeting antidepressant for patients who do not respond to treatment with first-line antidepressants with MDD and PTSD (Derakhshanian et al., 2021; Kritzer et al., 2022). It rapidly increases serotonergic neurotransmission and restores effective PFC synaptic connections (Holmes et al., 2022; Li et al., 2010). Evidence suggests that repeated ketamine infusions are efficacious in rapidly ameliorating both PTSD and MDD symptoms (Albott et al., 2018; Artin et al., 2022) and contribute to improvement of working memory in individuals with PTSD + MDD (Albott et al., 2022). Dai et al. reported significant improvement of both depression and PTSD symptoms in PTSD + MDD participants after a single infusion of ketamine administration (Dai et al., 2020). Artin et al. found distinct effects of ketamine on depression and PTSD symptoms (Artin et al., 2022), suggesting potentially different modes of action on corresponding underlying mechanisms. Recently, Johnston et al. provided an overview of ketamine use in psychiatric disorders and related comorbidities, and came to a conclusion that ketamine can effectively target multiple symptom domains, such as depression, anhedonia, and suicidal ideation (Johnston et al., 2024). However, few studies have explored the effects of ketamine infusions on brain structure and function in patients with PTSD + MDD to date. Dai et al. found a minor increase of the volume in the right opercular inferior frontal gyrus after a single ketamine infusion in patients with PTSD + MDD relative to baseline, suggesting that acute ketamine administration normalize structural alterations associated with depression but not PTSD symptoms (Dai et al., 2020). For functional alterations in PTSD + MDD, Albott et al. have recently proposed a research plan to verify the hypothesis that ketamine infusions could improve PTSD and MDD clinical symptoms by reversal of FC alterations (Albott et al., 2021). The researcher suggested that the completion of this study will strongly support the concept of a biologically based model of PTSD + MDD in the future. Overall, the effects of ketamine treatment on brain in patients with PTSD + MDD require more investigation. Additionally, predictive neuroimaging biomarkers for ketamine treatment in PTSD + MDD have not yet been systematically assessed. Repetitive TMS treatment As a type of noninvasive neurostimulation in clinical medicine, TMS has shown its ability to treat MDD and promise in several other conditions including PTSD (Huntley et al., 2023). Recent evidence suggests that TMS can be an effective treatment for patients with PTSD + MDD (Philip et al., 2022, 2016; Wilkes et al., 2020). Dorsolateral PFC, a core region of the central executive network responsible for top-down regulation of other networks such as DMN and SN, is the most common region targeted by TMS in psychiatric studies (Barredo et al., 2019). Studies in patients with MDD have demonstrated that TMS to the dorsolateral PFC could induce physiologic changes distal to the stimulation site, particularly in sgACC. Increased sgACC blood flow and higher sgACC metabolic activity at baseline predicted subsequent response to TMS, and posttreatment changes in blood flow and metabolism in the sgACC were associated with improved depression symptoms (Baeken et al., 2015; Kito et al., 2011, 2012). Philip et al. conducted the first study evaluating TMS-associated changes in FC in patients with PTSD + MDD, and underscored the involvement of sgACC, DMN, and SN in potential mechanisms of TMS response (Philip et al., 2018). In this study, Philip et al. found that both depressive and PTSD symptom improvements were associated with reduced sgACC-to-DMN connectivity and hippocampus-to-SN connectivity after TMS treatment in patients with PTSD + MDD. This study also indicated that different potential mechanisms correlated to MDD and PTSD symptom amelioration after TMS, including reduced connectivity between sgACC and visual regions related to PTSD symptom improvement and reduced connectivity between sgACC and somatosensory/motor regions related to depression amelioration (summarized in Table 2). Regarding neuroimaging predictors of TMS response, Philip et al. found that reduced sgACC-to-DMN connectivity and increased amygdala-to-PFC connectivity predicted TMS response in patients with PTSD + MDD (Philip et al., 2018), while in patients with MDD alone, Liston et al. found that hyperconnectivity between sgACC and DMN predicted subsequent response to TMS (Liston et al., 2014). Effects of different stimulation protocols (varied frequencies and intensities) and MRI data processing pipelines in the two studies need to be considered in comparing their findings, but differences are suggested. It raises issues about verification and comparison of neuroimaging predictors of TMS response in MDD alone, PTSD alone, and their comorbidity. Philip and colleagues further constrained tract-based probabilistic tractography via pre-TMS diffusion-weighted imaging data from patients with PTSD + MDD, and the weighted pathway averages of white matter integrity metrics were then extracted from four frontal white matter pathways: the forceps minor, ATR, cingulum, and uncinate fasciculi (Barredo et al., 2019). Then Philip et al. used backward stepwise regressions to evaluate whether the metrics in these fronto-limbic pathways (i.e. explanatory variables) accounted for significant variance in functional predictors of TMS outcome (i.e. dependent variables) revealed by their former study (Philip et al., 2018). They demonstrated that pretreatment FA in the left ATR was negatively associated with amygdala-to-PFC functional predictors for PTSD and depressive symptom improvements after TMS treatment, while FA in the right ATR was positively associated with these predictors (Barredo et al., 2019). These findings provide information about the underlying structural elements of functional predictors of treatment response to TMS. The reproducibility and reliability of these finding should be further verified. More efforts need be made to explore the neural mechanisms in relation to TMS action and biomarkers predicting and tracking response in PTSD + MDD populations, as well as corresponding similarities and differences among MDD alone, PTSD alone, and PTSD + MDD cohorts. Other related studies and corresponding suggestions for future research As an effective late-line treatment for refractory MDD, electroconvulsive therapy has been found associated with significant reductions of both PTSD and MDD symptoms in comorbid PTSD + MDD (Ahmadi et al., 2016; Callens and Sienaert, 2024), which may be predicted by response to dexamethasone suppression test (Ahmadi et al., 2018; Watts and Groft, 2010). However, the related underlying neural mechanisms have been rarely investigated. Similarly, external stimulation of the trigeminal nerve as an emerging adjunct to pharmacotherapy showed the efficacy for individuals with PTSD + MDD (Cook et al., 2016) with the neural mechanism poorly understood. The clinical implications and efficacy of cognitive–behavioral treatment program for individuals with PTSD + MDD have been examined (Nixon and Nearmy, 2011). Of note, a unified study examining brain activity induced by an emotional conflict task has reported that MDD and PTSD had similarly increased activation of cognitive control regions, implicating improved cognitive control activation as a transdiagnostic mechanism for the cognitive–behavioral treatment response (Yang et al., 2018b). The meta-analysis by Marwood et al. demonstrate that there are consistent activation decreases in ACC, inferior frontal gyrus and insula after psychological therapy across multiple disorders including MDD and PTSD (Marwood et al., 2018). The reproducibility and reliability of these findings need to be further verified. Specialized search strategies would be beneficial to a better understanding of the underlying transdiagnostic mechanisms for MDD and PTSD. A review by Moustafa et al. recommend a symptom-based approach investigating neural substrates associated with different clusters of symptoms (Moustafa et al., 2016), rather than the comparison of disorders. Using this approach, Satterthwaite et al. identified foci of resting-state functional dysconnectivity associated with depression severity in the bilateral amygdala across MDD and PTSD (Satterthwaite et al., 2016). Follow-up seed analyses revealed that depression severity in the pooled sample was associated with amygdalo-frontal hypo-connectivity in a network involving regions of bilateral dorsolateral PFC, ACC, and anterior insula. Future research adopting the symptom-based approach may help understand commonalities between MDD and PTSD considering their overlapping symptoms. The identification of neural substrates related to key clinical features in MDD and PTSD may help to tailor individualized programs to treat emotion and cognitive deficits. Furthermore, Seitz et al. recently investigated transdiagnostic dysfunction of DMN and some other key regions (e.g. ventral striatum and amygdala) with childhood maltreatment as the predictor in a transdiagnostic adult sample including patients with MDD, PTSD, and somatic symptom disorder (Seitz et al., 2024, 2023; Valencia et al., 2024). These studies showed us novel research approaches based on the shared risk factors. From connectome perspectives, Suo et al. systematically reviewed neuroimaging studies using graph theoretical approaches for six major psychiatric disorders including MDD and PTSD (Suo et al., 2018). Summaries of altered small-world properties showed no consistent alterations in MDD and PTSD, making cross-disease comparisons impossible. From the perspectives of segregation and integration, Suo et al. classified altered small-world properties into four patterns: namely, regularization, randomization, stronger small-worldization, and weaker small-worldization. Benefitting from these conceptualized patterns, future studies in MDD and PTSD may provide novel insights into the transdiagnostic and disorder-specific pathophysiological mechanisms underlying MDD and PTSD from a connectomic perspective. Early diagnosis and treatment of comorbidity would contribute to more rapid symptom reduction and any chronic illness progression. In the future machine learning may be beneficial to provide objective categorical diagnoses of MDD alone, PTSD alone, and PTSD + MDD, and to develop comprehensive models that can effectively predict an individual's risk for comorbidity as well as the treatment response. The predictive models may need to combine the underlying biological mechanisms of MDD and PTSD from dimensions of psychopathology including genetics, behavior, and neuropathology that may extend across diagnostic categories. It may help to identify change patterns involving interactions among genetics, environment exposure, and neuroimaging as predisposing factors for developing comorbidities. In addition, the effects of progressive depression in patients with PTSD remain unclear. Further longitudinal studies are crucial to illuminate possibly different neuroimaging presentations at different stages of the illness course, and to provide a better understanding of the interacting effect of PTSD and depression in patients with comorbidity. Conclusions Relevant neuroimaging studies to date have provided important information about the shared and disorder-specific neural features in MDD and PTSD, whereas it is difficult to obtain some reliable models from these findings considering their various analysis methods and different sample types. We just made some conceptual summaries at this stage. Direct comparisons in task-related brain functional activation in MDD and PTSD groups showed shared hypoactivation in the PFC, but higher activation in SN and fear processing regions in PTSD alone relative to MDD alone and comorbid PTSD + MDD groups during cognitive and emotional processes. Comparisons between PTSD + MDD and PTSD alone suggest that deficits in brain regions involved in fear and reward processing might be markers for distinguishing PTSD with and without MDD. Furthermore, both patients with PTSD and those with MDD displayed volume reductions in frontal areas including dorsolateral PFC and ACC. With respect to the treatments of ketamine and TMS in patients with PTSD + MDD, the underlying neural mechanisms associated with symptom improvements as well as predictive biomarkers for treatment effects need further investigation. Future research on the common and disease-specific features of MDD and PTSD may benefit from the novel approaches based on the symptom clusters and shared risk factors. Machine learning models combining genetics, behaviors, and neuropathology will be beneficial to predicting an individual's risk for PTSD + MDD comorbidity as well as treatment response. Supplementary Material